Radiolabeling of Epidermal Growth Factor with 99mTc and in Vivo Localization following Intracerebral Injection into Normal and Glioma-Bearing Rats
- 1 May 1997
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 8 (3), 289-295
- https://doi.org/10.1021/bc970031s
Abstract
High grade gliomas may have amplified expression of the epidermal growth factor receptor (EGFR) gene c-erb-B, which often is associated with increased expression of transmembrane EGFR. The purpose of the present study was to develop a method for labeling EGF with 99mTc and to determine whether the resulting radioligand would localize, following intracerebral injection, in rats bearing EGFR-positive gliomas. EGF has a relatively low molecular mass (approximately 6 kDa) compared to monoclonal antibodies, and this has allowed smaller bioconjugates, which should diffuse more rapidly within the brain and more effectively target disseminated glioma cells, to be constructed. In the present study, EGF has been labeled with either 131I or 99mTc, and in vitro uptake of the resulting radioligand has been investigated using C6EGFR rat glioma cells, which had been transfected with the EGFR gene. Cellular uptake of 131I radioactivity peaked after approximately 30 min of incubation with [131I]EGF, following which time it declined, while 99mTc radioactivity continued to increase over a 6 h incubation with [99mTc]-EGF. To determine if radiolabeled EGF had in vivo tumor-localizing properties, C6EGFR glioma cells were implanted stereotactically into the brains of Fischer rats. Four weeks later, either 99mTc- or 131I-labeled EGF was injected intracerebrally into normal or glioma-bearing animals using the same stereotactic coordinates. External gamma scintigraphy revealed that 131I radioactivity disappeared rapidly from the brain regions of tumor-bearing animals compared to 99mTc, approximately 50% of which remained in the tumor for up to 12 h. In contrast, only approximately 20% remained in the brains of non-tumor-bearing animals after 6 h. These studies are the first to describe a method for radiolabeling EGF with 99mTc and to detect it by external scintigraphy in the brains of tumor-bearing animals.Keywords
This publication has 15 references indexed in Scilit:
- Boron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruptionInternational Journal of Radiation Oncology*Biology*Physics, 1997
- A Phase I Study of an Anti-epidermal Growth Factor Receptor Monoclonal Antibody for the Treatment of Malignant GliomasNeurosurgery, 1996
- Boronated Epidermal Growth Factor as a Potential Targeting Agent for Boron Neutron Capture Therapy of Brain TumorsBioconjugate Chemistry, 1996
- Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomasJournal of Neurosurgery, 1991
- Effects of131I-EGF on cultured human glioma cellsJournal of Neuro-Oncology, 1990
- Polysomy of chromosome 7 is associated with amplification and overexpression of the EGF‐receptor gene in a human carcinoma cell line derived from a brain metastasisAPMIS, 1990
- Boron Neutron Capture Therapy of a Rat GliomaNeurosurgery, 1990
- RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENSAnnual Review of Biochemistry, 1987
- Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen.BMJ, 1985
- 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts.The Journal of cell biology, 1976